Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Zymeworks Inc. (ZYME) stock profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidate, zanidatamab, is a novel bispecific antibody in Phase 1 and Phase 2 clinical trials for biliary tract cancer, gastroesophageal adenocarcinomas, breast cancer, and colorectal cancer. ZW49 is a biparatopic anti-HER2 antibody-drug conjugate in Phase 1 clinical trials for advanced or metastatic HER2-expressing tumors. Zymeworks has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. The company also has licensing and research collaboration agreements with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies, and with Iconic Therapeutics, Inc. Zymeworks was incorporated in 2003 and is headquartered in Vancouver, Canada.

Key facts

SymbolZYME
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOKenneth H. Galbraith
Employees299
HeadquartersMiddletown, BC, CA
IPO2017-04-28
Websitewww.zymeworks.com

Explore ZYME on Vantafin

  • Zymeworks Inc. Overview
  • Zymeworks Inc. Financials
  • Zymeworks Inc. News
  • Zymeworks Inc. Events
  • Zymeworks Inc. SEC filings
  • Zymeworks Inc. Insider transactions
  • Zymeworks Inc. Transcripts

Frequently asked questions

What does Zymeworks Inc. (ZYME) do?
Zymeworks Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidate, zanidatamab, is a novel bispecific antibody in Phase 1 and Phase 2 clinical trials for biliary tract cancer, gastroesophageal adenocarcinomas, breast cancer, and colorectal cancer. ZW49 is a biparatopic anti-HER2 antibody-drug conjugate in Phase 1 clinical trials for advanced or metastatic HER2-expressing tumors. Zymeworks has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. The company also has licensing and research collaboration agreements with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies, and with Iconic Therapeutics, Inc. Zymeworks was incorporated in 2003 and is headquartered in Vancouver, Canada.
Where is ZYME stock listed?
Zymeworks Inc. trades under the ticker ZYME on NASDAQ.
How can I research ZYME's financials and filings?
Vantafin provides Zymeworks Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZYME profile.